Antibody-drug conjugates (ADCs) have emerged as a transformative class of therapeutics, combining the specificity of monoclonal antibodies with the potent cytotoxic effects of small-molecule drugs. By targeting specific antigens on cancer cells, ADCs deliver highly potent payloads while sparing healthy tissues, reducing systemic toxicity, and improving therapeutic outcomes.

Approved in 1998, trastuzumab (commonly known as Herceptin) marked a transformative milestone in oncology. Designed to target the human epidermal growth factor receptor 2 (HER2), trastuzumab provided a breakthrough for patients with HER2-positive breast cancer.

Copyright © 2023 Nudelman/ShutterstockRituximab was first approved by the FDA in 1997 for the treatment of CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). Its approval marked a significant milestone in oncology and paved the way for the development of antibody-based therapies. By targeting the

Over the past century, treatments like chemotherapy and radiation therapy have been developed for cancer. However, these therapies often lack the necessary specificity to deliver high enough doses to eliminate cancer cells while preventing intolerable toxicity.

DOI:10.1016/j.trecan.2024.07.002Bispecific antibodies (bsAbs) are a class of engineered therapeutic molecules designed to engage two different epitopes or antigens simultaneously, providing them with unique functionalities that go beyond traditional monoclonal antibodies. By targeting two distinct a

Antibody-drug conjugates (ADCs) have seen significant developments in regulatory review, with several notable announcements in the past few weeks. Innate Pharma received FDA clearance for its investigational new drug (IND) application for IPH4502, a novel topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.

Antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) represent two major advances in the field of cancer immunotherapy. While both approaches have achieved notable successes, especially in targeting specific cancers, their individual limitations, such as restricted efficacy in certain tumor types and adverse side effects, present challenges. Combining these two therapies has emerged as a promising strategy to address these shortcomings.

Bispecific antibodies are rapidly transforming the therapeutic landscape, especially in oncology and autoimmune diseases. Such recombinant molecules can bind to two different antigens at the same time, offering greater specificity in targeting disease pathways. Since their introduction, the area of bispecifics has held tremendous promise in oncological cancers like multiple myeloma and lymphomas.

T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is an immune receptor that plays a key role in suppressing T-cell activation and proliferation. As a newly identified checkpoint, it is highly expressed on various immune cells, including CD4+ and CD8+ T cells, NK cells.

News from the IASLC 2024 World Conference on Lung Cancer (WCLC24) has provided several updates on the clinical trial space for non-small cell lung cancer (NSCLC), with several antibody-based drugs at the forefront. NSCLC is the most common type of lung cancer, accounting for about 85% of all cases.

Explore how bispecific antibodies (BsAbs) revolutionize in vivo research, enhancing oncology, immunotherapy, & drug development with dual-targeting precision.

​A recent editorial by researchers at Yale University School of Medicine describes how we are entering the golden age for antibody-drug conjugates (ADCs) in gynecologic cancer, which includes difficult to treat tumors such as uterine carcinosarcomas and platinum-resistant ovarian cancer.

Explore how antibody-dependent cellular phagocytosis (ADCP) targets cancer cells using monoclonal antibodies like rituximab & trastuzumab. Learn about FcγR, complement pathways, & challenges like CD47 in therapeutic efficacy.

Discover how immune checkpoint inhibitors like PD-1 & CTLA-4 blockers are transforming cancer treatment. Learn about synergies with antibody therapeutics.

Immune checkpoint blockade antibody therapy is an approach in cancer treatment that uses the body's immune system to target and destroy cancer cells. Immune checkpoints are regulatory pathways in immune cells that cancer cells exploit to evade detection. Key immune checkpoints include PD-1, PD-L1, and CTLA-4. By blocking these pathways, antibodies like pembrolizumab, nivolumab, and ipilimumab allow T-cells to recognize and attack cancer cells more effectively.